Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07075406 · ClinicalTrials.gov registry record
A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 250
- Enrollment target
NCT07075406: Completed study, sponsored by Bristol-Myers Squibb.
NCT07075406 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 250 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07075406 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes
Interventions
- DRUG Luspatercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2025-08-01 |
What the finished NCT07075406 record still lists
NCT07075406 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Luspatercept is the first listed.
NCT07075406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07075406 about?
NCT07075406 is a clinical study titled "A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept". The purpose of this study is to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes
What is the current status of trial NCT07075406?
This trial is currently completed. The enrollment target is 250 participants. The study started on 2024-11-01. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT07075406?
The interventions under investigation include: Luspatercept (DRUG).
Who is sponsoring clinical trial NCT07075406?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI